Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors

Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors

Von Hippel–Lindau (VHL) loss is the hallmark event characterizing the clear cell renal cancer subtype (ccRCC). Carriers of germinal VHL mutations have an increased prevalence of kidney cysts and ccRCC as well as hemangioblastoma, pheochromocytoma and pancreatic neuroendocrine tumors. In both sporadi...

Full description

Bibliographic Details
Main Authors: Cristina Suárez, Maria Vieito, Augusto Valdivia, Macarena González, Joan Carles
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Medical Sciences
Subjects:
VHL
HIF2A
clear cell renal cancer
Belzutifan
kidney cancer
Online Access:https://www.mdpi.com/2076-3271/11/3/46

Similar Items

Similar Items